These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab). Kainer M; Antes B; Wiederkum S; Wozniak-Knopp G; Bauer A; Rüker F; Woisetschläger M Arch Biochem Biophys; 2012 Oct; 526(2):154-8. PubMed ID: 22634259 [TBL] [Abstract][Full Text] [Related]
23. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730 [TBL] [Abstract][Full Text] [Related]
24. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. Chamow SM; Zhang D; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP J Hematother; 1995 Oct; 4(5):439-46. PubMed ID: 8581382 [TBL] [Abstract][Full Text] [Related]
25. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells. Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185 [TBL] [Abstract][Full Text] [Related]
26. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design. Caaveiro JM; Kiyoshi M; Tsumoto K Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522 [TBL] [Abstract][Full Text] [Related]
27. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286 [TBL] [Abstract][Full Text] [Related]
28. Biophysical Evaluation of Rhesus Macaque Fc Gamma Receptors Reveals Similar IgG Fc Glycoform Preferences to Human Receptors. Crowley AR; Osei-Owusu NY; Dekkers G; Gao W; Wuhrer M; Magnani DM; Reimann KA; Pincus SH; Vidarsson G; Ackerman ME Front Immunol; 2021; 12():754710. PubMed ID: 34712242 [TBL] [Abstract][Full Text] [Related]
29. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029 [TBL] [Abstract][Full Text] [Related]
30. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280 [TBL] [Abstract][Full Text] [Related]
31. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs. Boesch AW; Miles AR; Chan YN; Osei-Owusu NY; Ackerman ME MAbs; 2017 Apr; 9(3):455-465. PubMed ID: 28055295 [TBL] [Abstract][Full Text] [Related]
32. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744 [TBL] [Abstract][Full Text] [Related]
33. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Rudnick SI; Lou J; Shaller CC; Tang Y; Klein-Szanto AJ; Weiner LM; Marks JD; Adams GP Cancer Res; 2011 Mar; 71(6):2250-9. PubMed ID: 21406401 [TBL] [Abstract][Full Text] [Related]
34. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity. Jung ST; Kelton W; Kang TH; Ng DT; Andersen JT; Sandlie I; Sarkar CA; Georgiou G ACS Chem Biol; 2013 Feb; 8(2):368-75. PubMed ID: 23030766 [TBL] [Abstract][Full Text] [Related]
35. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Harms BD; Kearns JD; Iadevaia S; Lugovskoy AA Methods; 2014 Jan; 65(1):95-104. PubMed ID: 23872324 [TBL] [Abstract][Full Text] [Related]
36. The role of non-immune IgG in controlling IgG-mediated effector functions. Segal DM; Dower SK; Titus JA Mol Immunol; 1983 Nov; 20(11):1177-89. PubMed ID: 6228721 [TBL] [Abstract][Full Text] [Related]
37. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830 [TBL] [Abstract][Full Text] [Related]